Compare Harmony Gold Mining Co. (HMY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Merck & Co., Inc. — how do they compare? Harmony Gold Mining Co. trades at $19.85 (market cap $12.24B), while Merck & Co., Inc. trades at $132.93 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 26.3× Harmony Gold Mining Co.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| HMY | MRK | |
|---|---|---|
Market Cap | $12.24B | $321.77B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $131.84 |
52-Week Low | $12.61 | $77.60 |
Enterprise Value | $12.58B | $368.53B |
Dividend Yield | 2.09% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $19.88, down 0.1% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, supported by a strategic pivot to gold-copper production. Recent news highlights operational progress, including copper profit growth and diversification efforts.
HMY offers value with a P/E of 12.26 and robust profitability margins, but faces risks from gold price volatility and mixed analyst sentiment. The stock's outlook is supported by earnings growth and diversification, though investor caution is warranted due to Fed policy sensitivity and execution risks in expansion.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
